This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Accuray Receives FDA 510(k) Clearance For New CyberKnife® M6™ Series, Merging Multileaf Collimation With Non-Isocentric Robotic Delivery

SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ --  Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new CyberKnife ® M6 Series. The CyberKnife M6 Series features expanded clinical capabilities, reduced treatment times and an enhanced patient experience. The new CyberKnife M6 FIM and FM Systems, featuring the InCise™ Multileaf Collimator combines the benefits of beam shaping with the flexibility of non-isocentric, non-coplanar delivery offering unmatched clinical capabilities and expanding the number of patients eligible for treatment.

The new InCise Multileaf Collimator was designed specifically for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments, giving the system the capability to extend its radiosurgical accuracy into a broader field of applications, meeting radiosurgery and radiotherapy needs. With the InCise Multileaf Collimator, the CyberKnife M6 Series can be used to treat large and irregular tumors more efficiently with excellent dose gradients. This added flexibility expands the number of patients eligible for treatment with the CyberKnife M6 Series.

"The CyberKnife M6 Series offers a collimation option to address a variety of clinical applications, including large, complex tumors. The InCise Multileaf Collimator is designed to sculpt a single radiation beam to match the exact contour of a tumor, which would significantly minimize the amount of radiation to the surrounding tissues and reduce the treatment time," said Dwight Heron, M.D., Professor and Vice-Chairman, Radiation Oncology, Otolaryngology, Head & Neck Surgery at the University of Pittsburgh School of Medicine. "Now many targets previously unsuited for SRS/SBRT can be treated more quickly and effectively than before."

Unlike any other MLC on the market, the InCise Multileaf Collimator can not only move its leaves to create complex shapes, it can also be moved around the patient by a robot in 3D to deliver precisely shaped beams to the target from hundreds of unique angles. This non-isocentric, non-coplanar delivery enables the highest level of accuracy and healthy tissue sparing. The added flexibility is further enhanced when combined with the CyberKnife's Synchrony® System, which enables the CyberKnife M6 System to track tumors as they move and automatically correct for their movement throughout treatment.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs